Trial · NCT06478797
Registered outcomes19
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 19 of 19
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Survival free of organ support at 28 days | From time of randomization until 28 days, if death occurs, time is set to 0 days | Organ support will be defined as invasive ventilation support, cardiovascular organ support (inotropic or ECMO support), and renal replacement therapy |
| Secondary | Recuitment rates | 12 months | Secondary feasibility outcome 1 |
| Secondary | Proportion of eligible randomised | 12 months | Other feasibility 2 |
| Secondary | Proportion of eligible consented using perspective consent and consent to continue | 12 months | Other feasibility 3 |
| Secondary | Time to initiation of inotropes between the control and the early inotrope arm | 24 hours | Other feasibility 4 |
| Secondary | Amount of fluid delivered (in mLs per kg) during the first 24 h between the control and the early inotrope arm | 24 hours | Other feasibility 5 |
| Secondary | Protocol violations | 12 months | Other feasibility 6. Percentage of patients not treated according to the assigned group. |
| Secondary | Survival free of inotrope support at 7 days | 7 days | Secondary exploratory clinical outcome 1 |
| Secondary | Survival free of invasive ventilation support at 7 days | 7 days | Secondary exploratory clinical outcome 2 |
| Secondary | 28-day mortality | From time of randomization until 28 days | Secondary exploratory clinical outcome 3 |
| Secondary | Survival free of PICU censored at 28 days | 28 days | Secondary exploratory clinical outcome 4 |
| Secondary | PICU length of stay | 28 days | Secondary exploratory clinical outcome 5 |
| Secondary | Hospital length of stay | 28 days | Secondary exploratory clinical outcome 6 |
| Secondary | Functional Status Score at 28 days | 28 days | Secondary exploratory clinical outcome 7 |
| Secondary | Modified Pediatric Overall Performance Category at 28 days | 28 days | Secondary exploratory clinical outcome 7 |
| Secondary | Amount of fluid (mLs per kg) received during the first hour, and by 4, 12, and 24 hour post enrolment | 24 hours | Secondary exploratory clinical outcome 8 |
| Secondary | Proportion of patients with lactate <2 mmol/l at 6, 12, and 24 hours post enrolment | 24 hours | Secondary exploratory clinical outcome 9 |
| Secondary | Time to reversal of tachycardia during the first 24 h | 24 hours | Secondary exploratory clinical outcome 10 |
| Secondary | Time to shock reversal, defined as cessation of inotropes for at least 4 h censored at 28 days | 28 days | Secondary exploratory clinical outcome 11 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06478797/registered